Small cell lung cancer (SCLC) is an invasive and high-grade neuroendocrine malignant tumor. It is characterized by short doubling time, high proliferation rate, and early extensive metastasis. SCLC is sensitive to radiotherapy and chemotherapy in the initial stage; however, it can easily relapse and develop drug resistance. In the past five years, there has been a resurgence of research on SCLC worldwide, including the establishment of SCLC cells, the development of related genetically engineered mouse models (GEMMs) and the establishment of patientderived xenograft models (PDXs). These studies have identified new potential therapeutic vulnerabilities for SCLC, leading to new clinical trials. In this perspective, the establishment, application, and advantages and disadvantages of three preclinical research models of SCLC are systematically summarized.
remained progression-free at one year. The improved median survival for advanced SCLC ranged from 10.3 to 12.3 months [5] . Clearly, more effective regimens are needed for SCLC therapy.
ESTABLISHMENT OF SCLC CELL LINES
In 1970, Shimosato Y. et al. of Tokyo National Cancer Center extracted SCLC cells from metastatic lymph nodes of oat cell carcinoma and established a human lung cancer cell line. The cell line is named "OAT cell line" due to oat cell carcinoma [6] . The established SCLC cell lines were composed of loose or tightly aggregated floating cells, which grew freely in the culture medium. From 1976 to 1991, the Dartmouth group successfully cultured 122 SCLC cell lines, known as "Dartmouth cell lines" [7] . In the initial stage, the selection of culture medium was a difficult point, as the conventional RPMI-1640 medium containing fetal bovine serum could not meet the requirements of the sustainable selective growth of SCLC cells. In subsequent studies, a specific serum-free medium was developed by Elizabeth Simms. Then, five supplements (hydrocortisone, insulin, transferrin, estradiol, and selenium, HITES) were identified and added to support the continuous replication of established SCLC cells, which was hence known as "HITES medium" [8] . After the SCLC cells are established, researchers usually use RPMI-1640 medium containing fetal bovine serum or completely serum-free limited medium to maintain the established cell lines [9] .
From the study conducted by the National Cancer Institute of the United States [10] , considerable heterogeneity was found in the morphology of 50 SCLC cell lines. Most cell lines (46 of 50, 92%) grew into dense to loosely arranged suspended aggregates (Types 1-3), while three cell lines (6%) grew into adherent monolayer cultures (Type 4). One of the 50 SCLC cell lines showed a mixed form of Types 2 and 4. Based on the expression of four biomarkers, SCLC cell lines can be divided into two categories. One category is the classical SCLC cell line with increased expression of L-dopa decarboxylase (DDC), bombesin-like immunoreactivity (BLI), neuronspecific enolase (NSE) and creatine kinase brain isozyme (CK-BB). The other is a mutant SCLC cell line lacking key amine precursor uptake and decarboxylation enzymes DDC and CK-BB. There are variants of SCLC cells that do not express BLI, but still have an increased expression of NSE and CK-BB.
Using immortalized human bronchial epithelial cells as a control, researcher can determine the genetic and epigenetic differences between tumor cells and normal cells to study the pathogenesis of SCLC and to screen and test of novel chemotherapeutic drugs [11, 12] . NeuroD1-low. These tumors lack neuroendocrine markers and appear to fall into YAP1-high or POU2F3-high subtypes [13] .
There are still many limitations in the current establishment of SCLC cell lines. Firstly, although these cells retain driving proto-oncogenes, the lack of interaction with tumor microenvironment may limit the study of immunotherapy or vascular targeted therapy. Secondly, although they are very helpful for in vitro experiments, e.g., drug screening and targeted gene therapy testing, the application of those screening or testing results for in vivo study needs further evaluation. Thirdly, most of the cell lines were cultured in two dimensions, and the cultured SCLC cells maintained the appearance and differentiation characteristics of SCLC cytology, but the ability of differentiation after inoculation into the animal model remained to be observed. Therefore, although the establishment of SCLC cell lines has accelerated the research process of SCLC, there are still problems in many aspects.
Although a cell line is not the ideal model system, it complements the disadvantage of tumor tissue and animal models in studying SCLC. The establishment of SCLC cell line has accelerated the research process of SCLC. Many variant lines confirmed the amplification of MYC gene family in SCLC and the important role of hedgehog pathway and Notch pathway in SCLC [14] [15] [16] [17] . At the same time, the SCLC cell lines provide a suitable model for genome (high throughput DNA sequencing) [18] , transcriptome (microarray analysis) [19, 20] , methylation (detection of whole genome methylation sequence) [21] and microRNA analyses [22] . Since the established SCLC cell lines retain the original neuroendocrine phenotype of SCLC cells, they provide a good tool for studying SCLC heterogeneity, transformation, and epigenetics.
GENETIC ENGINEERING MOUSE MODELS (GEMMS)
Mouse models are widely used in cancer therapeutics to evaluate the efficacy of novel drug candidates in vivo. Historically, these models mainly relied on xenograft systems that use human tumor cell lines and immunodeficient mice to obtain xenograft tumors [23] . However, the results obtained by these models cannot fully predict the clinical outcome and prognosis of SCLC [24] . Therefore, it is very important to find more preclinical models of SCLC to develop new and effective treatment schemes. Several genetic engineering mouse models were developed in recent years.
It was found that the inactivation rate of Rb1 and Tp53 in SCLC patients was as high as 90% [25, 26] . Table 1 summarizes several representative GEMMs. histological appearance of the resulting tumors. However, due to the differences between the targeted mouse gene products and the human corresponding gene products, many drugs that are effective in mouse models have no effect in clinical trials [31, 32] , which suggests that the main problem in using mouse models to simulate human cancer is that there are inherent biological differences between the two organisms.
Therefore, the use of GEMMs to predict clinical reactions and evaluate drug efficacy is debatable.
PATIENT-DERIVED XENOGRAFT MODELS (PDXS)
PDXs are constructed by directly inoculating tumor tissue or cells from a patient's tumor to immunodeficient mice [33] . They are commonly used to analyze the growth, metastasis and drug sensitivity of human tumors.
Compared with GEMMs, PDXs are relatively time-, labor-and costeffective. Furthermore, PDXs can be used to design personalized targeted therapy [34] .
There are two main methods for establishing PDXs: subcutaneous inoculation and intracranial inoculation. Subcutaneous inoculated tumor presents expansive growth, less invasiveness and no metastasis, while intracranial inoculated tumor is highly invasive and lethal. Moreover, intracranial inoculated tumor has a higher success rate of xenograft and requires fewer cells to induce tumor formation [35] . PDXs lay the foundation for acquiring continuous cell lines and tumor tissues for further study. In recent years, researchers found that circulating tumor cells (CTCs)
can be detected in 70%-95% of SCLC patients [36] . New progress has been made in the study of tumor transplantation by transplanting CTCs into mice (CDX model) [37] . Studies have shown that patients with SCLC show a higher CTCs load. CTCs from SCLC patients can effectively form tumors when transplanted into immunodeficient mice [38] . CDX tumor reproduces the histologic characteristics of human SCLC and reflects the effect of chemotherapy. The combined investigation of the preclinical therapeutic study in CDX model with gene profile analysis of human SCLC specimen is a potential and powerful approach to identify chemotherapyresistant mediators and novel drug candidates. In several clinical trials of SCLC, the CTCs count has been used as an exploratory biomarker of predicting treatment response and drug resistance [39, 40] . It can also be used as a pharmacodynamic biomarker in drug development to guide the use of the best therapeutic dose, which has revolutionized the current relatively crude maximum tolerable dose.
PDXs have a wide range of use, which is beneficial to study the tumorigenicity, histological appearance, tumor stem cells and the gene interaction of SCLC. The most common application is in vivo trials of conventional and targeted therapy [41] . we obtain the maximum utility from the preclinical models.
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